Basel Medical Group Ltd (BMGL) Closes Registered Direct Offering

Warrant holders can receive 6,000,000 additional ordinary shares without paying additional cash to the company.

Rhea-AI Summary

Basel Medical Group (Nasdaq: BMGL) closed a registered direct offering of units, raising US$7.98 million in gross proceeds. Estimated net proceeds are approximately US$7.28 million. The 6,000,000 units sold at US$1.33 each included one ordinary share and one Common Warrant to purchase another share; no pre-funded warrants were issued. Cathay Securities acted as exclusive placement agent.

Outstanding ordinary shares increased from 1,582,111 to 7,582,111. Warrant holders may receive an aggregate of 6,000,000 additional shares through a zero-cash exercise option. The company does not expect additional funds from warrant exercises. Company share issuance and financing transactions require placement-agent consent for 180 days, subject to stated exceptions. Executives, directors and certain shareholders owning at least 5.0% before the offering also entered 180-day lock-ups, subject to exceptions and placement-agent approval.

1 point · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointUS$7.98 million gross proceeds raised, with estimated net proceeds of approximately US$7.28 million. 1.4× market cap

Negative

• Major point6,000,000 new ordinary shares at US$1.33 per unit increased outstanding shares from 1,582,111 to 7,582,111.
• Minor point. Forward-looking: it has not happened yet and may not happen.6,000,000 Common Warrants allow additional share issuance without cash payment; the company expects no additional exercise funds.
• Minor point180-day restrictions require placement-agent consent for company share issuance and financing transactions, subject to stated exceptions.

News Explained

The company intends to use all estimated net proceeds of US$7.28 million for general working capital, mergers and acquisitions, and other general corporate purposes.

Key Figures

Units sold: 6,000,000 units Gross proceeds: US$7.98 million Net proceeds: US$7.28 million +5 more

Units sold

6,000,000 units

Registered direct offering

Gross proceeds

US$7.98 million

Offering proceeds

Net proceeds

US$7.28 million

Estimated net proceeds

Offering price

US$1.33 per Unit

Public offering price

Zero-cash warrant shares

6,000,000 Ordinary Shares

Could be issued without additional cash to the company

Ordinary Shares outstanding

1,582,111 before; 7,582,111 after

Immediately before and upon completion of the offering

Common Warrant exercise price

110% of the public offering price per Unit

Immediately exercisable

Common Warrant term

Five years

Expires five years from issuance

Previous Offering Reports

1 past event · Latest: Oct 08

Same Type 1 event

1. Oct 08

   Offering pricing

   24h Move

   +9.8%

   Set the terms for the same 6,000,000-unit sale now reported closed.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

registered direct offering, zero cash exercise price option, lock-up agreements, form f-1

4 terms

registered direct offering financial

"closed its registered direct offering of 6,000,000 units"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

zero cash exercise price option financial

"by means of a zero cash exercise price option"

A contractual right to obtain company shares on exercise without making a cash payment of the strike price. Instead of the option holder handing over money, the company delivers fewer shares (or withholds a portion of the shares issuable) equal in value to the exercise price and any required tax withholding, or issues the net number of shares after offsetting the price. Practically this lets the holder convert options into equity with no out-of-pocket cost; structurally it is a form of cashless or net exercise and changes how many new shares are issued and how dilution and tax withholding are handled.

lock-up agreements financial

"have entered into lock-up agreements in connection with the offering"

A lock-up agreement is a contract that prevents company insiders—founders, employees, and early investors—from selling their shares for a set period after a public stock offering. It matters to investors because it keeps a large block of shares off the market temporarily; when the lock-up ends, those holders can sell and this increased supply can cause the stock price to fall, similar to a timed release that suddenly opens a valve.

form f-1 regulatory

"registered pursuant to the Company’s effective registration statement on Form F-1"

A Form F-1 is the document a non-U.S. company files with U.S. regulators when it wants to sell stock or other securities to U.S. investors. It lays out the company’s business, finances, risks and how the offering will work, acting like a product manual and ingredient list so investors can judge what they’re buying. For investors, it’s a key source of verified information used to compare opportunities and assess potential reward and risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Singapore, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”) today closed its registered direct offering of 6,000,000 units, raising gross proceeds of US$7.98 million and estimated net proceeds of approximately US$7.28 million. The Company intends to use all of the net proceeds from this offering for general working capital purposes, mergers and acquisitions and other general corporate purposes. 

As previously announced, the Company entered into a placement agency agreement with Cathay Securities, Inc., as the placement agent (the “Placement Agent”), as well as a securities purchase agreement with certain purchasers, each dated October 7, 2026, pursuant to which the Company issued and sold 6,000,000 units (the “Units”), at a public offering price of US$1.33 per Unit, each consisting of one ordinary share with no par value (each an “Ordinary Share” and collectively the “Ordinary Shares”) or one Pre-Funded Warrant in lieu thereof (defined below) of the Company, and one warrant (“Common Warrant”), each to purchase one Ordinary Share. No Pre-Funded Warrants were issued in the offering.

The Ordinary Shares are listed on the Nasdaq Capital Market under the symbol “BMGL”. The Common Warrants will not be listed or quoted on any exchange. The Ordinary Shares issued and to be issued upon warrant exercise and pursuant to this offering are registered pursuant to the Company’s effective registration statement on Form F-1 (File No. 333-298988) (the “Registration Statement”).

Each Common Warrant is exercisable immediately on the date of issuance at an exercise price per share equal to 110% of the public offering price of each Unit sold in this offering and will expire five years from the date of issuance. A holder of Common Warrants may, at any time following the closing of this offering within the exercise period and in its sole discretion, exercise its Common Warrants in whole or in part by means of a zero cash exercise price option, in which the holder will receive the number of Ordinary Shares that would be issuable upon a cash exercise of the Common Warrant, without payment of additional consideration, or a total of 6,000,000 additional Ordinary Shares in the aggregate. As a result, we will likely not receive any additional funds and do not expect to receive any additional funds upon the exercise of the Common Warrants. If all of the 6,000,000 Common Warrants offered to investors in this offering are exercised on a zero cash basis, an aggregate of 6,000,000 Ordinary Shares would be issued upon such zero cash exercise without payment to us of any additional cash.

Immediately prior to this offering, the Company had a total of 1,582,111 Ordinary Shares issued and outstanding. Immediately upon the completion of the offering, the Company has a total of 7,582,111 Ordinary Shares issued and outstanding and a total of 6,000,000 Common Warrants issued and outstanding.

The executive officers, directors and certain shareholders beneficially owning 5.0% or more of the Company’s ordinary shares prior to this offering have entered into lock-up agreements in connection with the offering. Under these agreements, the Company and each of these persons may not, without the prior written approval of the Placement Agent, offer, sell, contract to sell or otherwise dispose of or hedge Ordinary Shares or securities convertible into or exchangeable for Ordinary Shares, subject to certain exceptions. The restrictions contained in these agreements will be in effect for a period of 180 days for the Company and 180 days for the executive officers, directors and such shareholders, after the date of the closing of this offering. The Company has agreed that, for a period of 180 days following the closing date of this offering, it will not, without the prior written consent of the Placement Agent, directly or indirectly issue, offer, sell, contract to sell, grant any option to purchase, or otherwise dispose of any Ordinary Shares or any securities convertible into, exercisable for, or exchangeable for Ordinary Shares, other than a prospectus filed with the Commission pursuant to Rule 424(b) in connection with this offering, supplements or amendments to registration statements or supplements previously filed. The Company has also agreed that, during the same 180 days, it will not enter into or consummate any financing or capital-raising transaction, including any equity line of credit, equity financing, convertible bond, convertible note, other equity-linked financing, or variable rate transaction, without the prior written consent of the Placement Agent.

Cathay Securities, Inc. acted as exclusive placement agent in connection with this offering. Sichenzia Ross Ference Carmel LLP acted as counsel to the Company regarding U.S. securities law matters. Hunter Taubman Fischer & Li LLC acted as U.S. securities counsel for the placement agent.

The securities described above are being offered pursuant to the Registration Statement, which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on September 29, 2026. The offering is being made only by means of a prospectus which is a part of the Registration Statement. A preliminary prospectus relating to the offering has been filed with the SEC. Copies of the final prospectus relating to the offering may be obtained from Cathay Securities, Inc., 40 Wall Street, Suite 3600, New York, NY 10005, Attention: Shell Li, or by calling +1 855-939-3888, by email request to service@cathaysecurities.com.

Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more complete information about the Company and the offering. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company’s securities in any state or jurisdiction in which such offers, solicitations or sales would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. Any offers, solicitations, or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

About Basel Medical Group Ltd

Basel Medical is a Singapore-based provider of orthopedic and trauma services, sports medicine, orthopedic procedures and surgery, as well as neurosurgical treatments, executive health screening services, occupational medicine, rehabilitation, mental and women’s health and general medical practices. Our operations are based in Singapore, with our clinics being located at Suntec City Mall, Macpherson Road, Toa Payoh, Margaret Drive, Tampines, Gateway East and Gleneagles Medical Centre. Over the last 20 years, our group has forged strong and lasting relationships with a wide corporation clientele, particularly those in the construction, marine and oil & gas industries, which underpin our robust business model. As an medical service provider in Singapore with a track record of over 20 years, we are well-positioned to ride the wave of growth opportunities in the private healthcare industry in Singapore and across Southeast Asia driven by ageing populations, rising income levels, increasing private insurance coverage, increasing expenditure on healthcare, growing sports participation rate and Singapore’s position as a premium destination for healthcare services in Asia. Our management and medical practitioner team comprises a roster of orthopedic and neurosurgery specialists, general practitioners, corporate finance and healthcare partnership specialists. Basel Medical Group Ltd serves as the holding company of our group and we conduct our operations through our operating subsidiaries based in Singapore. For more information, please visit the Company’s website: www.baselmedical.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, which involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “aim”, “anticipate”, “believe”, “estimate”, “expect”, “going forward”, “intend”, “may”, “plan”, “potential”, “predict”, “propose”, “seek”, “should”, “will”, “would” or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC.

Media Contact:

Basel Medical Group Ltd
Phone: +65 6291 9188
Email: contact@baselmedical.com
Website: www.baselmedical.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did Basel Medical Group raise in its registered direct offering?

Basel Medical Group raised US$7.98 million in gross proceeds, with estimated net proceeds of approximately US$7.28 million. It sold 6,000,000 units at US$1.33 per unit, each containing one ordinary share and one Common Warrant.

How does BMGL's offering affect its outstanding shares?

BMGL's outstanding ordinary shares increased from 1,582,111 to 7,582,111 upon completion of the offering. If all 6,000,000 Common Warrants are exercised on a zero-cash basis, another 6,000,000 ordinary shares would be issued without additional cash payment to the company.

What are the exercise terms of BMGL's Common Warrants?

The Common Warrants are exercisable immediately upon issuance at an exercise price equal to 110% of the public offering price per unit and expire five years from issuance. Holders may instead use the zero-cash exercise option following closing within the exercise period. The warrants will not be listed or quoted on any exchange.